![B cell lymphocyte activation by ab168061. Method: Peripheral Blood Mononuclear Cells (PBMCs) were incubated at 37°C, 5% CO 2 for 48 hours in 48 well plates (1 x 10 6 cells/well). Each well contained 200µl serum free test media with serially diluted ab168061. After treatment, cells were washed and dual-stained with mouse anti-human CD19–PE and mouse anti-human CD86–APC and analyzed by flow cytometry. The data are presented as the percent of CD19 positive B cells that co-stain as CD86 positive, at each concentration of ab168061.](http://www.bioprodhub.com/system/product_images/pp_products/2/sub_1/470_CD40L-Proteins-and-Peptides-ab168061-4.jpg)
B cell lymphocyte activation by ab168061. Method: Peripheral Blood Mononuclear Cells (PBMCs) were incubated at 37°C, 5% CO 2 for 48 hours in 48 well plates (1 x 10 6 cells/well). Each well contained 200µl serum free test media with serially diluted ab168061. After treatment, cells were washed and dual-stained with mouse anti-human CD19–PE and mouse anti-human CD86–APC and analyzed by flow cytometry. The data are presented as the percent of CD19 positive B cells that co-stain as CD86 positive, at each concentration of ab168061.